Chemical genetic interactions elucidate pathways controlling tuberculosis antibiotic efficacy during infection

Area of Science:

• Microbiology
• Genetics
• Pharmacology

Background:

• Tuberculosis (TB) treatment requires lengthy multidrug regimens, driving the need for novel therapeutic strategies.
• Optimizing TB therapy involves understanding chemical-genetic interactions (CGIs) to identify new drug targets and synergistic combinations.
• Current CGI studies are primarily *in vitro*, limiting insights into the host environment's impact on drug efficacy.

Purpose of the Study:

• To characterize *in vivo* chemical-genetic interactions (CGIs) of Mycobacterium tuberculosis (Mtb) essential genes with TB drugs in a mouse infection model.
• To compare *in vivo* CGIs with *in vitro* findings and identify host-specific interactions.
• To elucidate the mechanism of pyrazinamide (PZA) activity *in vivo* and discover novel therapeutic targets.

Main Methods:

• Utilized a conditional mutant library targeting 467 essential Mtb genes.
• Characterized CGIs with TB drugs directly within a mouse infection model.
• Analyzed drug-specific and drug-agnostic effects, including during multidrug treatment.

Main Results:

• *In vivo* CGIs significantly differ from *in vitro* identified interactions.
• Identified both drug-specific and drug-agnostic effects, with many preserved during combination therapy.
• Elucidated PZA's complex *in vivo* activity, highlighting the roles of coenzyme A synthesis, iron limitation, thiamine, and purine metabolism.

Conclusions:

• The study maps unique *in vivo* CGIs, providing a framework for understanding TB drug action in the host environment.
• Findings reveal novel metabolic dependencies that enhance PZA efficacy, suggesting new therapeutic avenues.
• Identified unique *in vivo* targets for developing more effective antitubercular drugs and combination therapies.